Here are the 10 most prevalent conditions that result in malpractice lawsuits.
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
FDA extends review of ruxolitinib cream for pediatric atopic dermatitis
The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.
Food Insecurity and the Dangers of Infant Formula Dilution
Caffeine proposed as a potential tool in reducing risk of SIDS
Caffeine may protect infants from SIDS by reducing oxygen drops, offering a potential new tool alongside safe sleep practices, a recent study suggests.
Demystifying Infant Formula
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
In this video interview, Michael Daines, MD, explains phase 3 data for Panzyga (Octapharma) for pediatric acute- onset neuropsychiatric syndrome (PANS).
John Browning, MD, explains dermatological questions to ask, answer in primary care
John Browning, MD, highlights why pediatricians should feel comfortable prescribing recent non-steroidals, and what questions to ask patients in office.